Latest Breaking News On - Antisense oligonucleotide drug - Page 1 : comparemela.com

SPL84 shows good safety profile in 1st clinical trial in CF | CF treatment targets specific mutation called 3849+10 kb C-to-T

SPL84 shows good safety profile in 1st clinical trial in CF | CF treatment targets specific mutation called 3849+10 kb C-to-T
cysticfibrosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cysticfibrosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

Gili hartEuropean unionAntisense oligonucleotide drugNucleic acid

SpliSense Successfully Completed Phase 1 Study of SPL84, RNA-Based Therapy, for the Treatment of Cystic Fibrosis

/PRNewswire/ SpliSense, a biopharmaceutical company developing transformative RNA-based therapies for pulmonary diseases including cystic fibrosis (CF),.

Israel generalGili hartPrnewswire splisenseLisrael biotech fundHebrew university of jerusalemCystic fibrosis foundationIntegra holdingsNucleic acid therapeuticsChief executive officerAntisense oligonucleotide drugNucleic acidBatsheva keremHebrew universityBiotel limitedCystic fibrosis